- Home
- HEPS vs APLT Comparison
HEPS vs APLT Comparison
Compare HEPS & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- APLT
- Stock Information
- Founded
- HEPS 2000
- APLT 2016
- Country
- HEPS Turkey
- APLT United States
- Employees
- HEPS N/A
- APLT N/A
- Industry
- HEPS Catalog/Specialty Distribution
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- APLT Health Care
- Exchange
- HEPS Nasdaq
- APLT Nasdaq
- Market Cap
- HEPS 1.1B
- APLT 971.6M
- IPO Year
- HEPS 2021
- APLT 2019
- Fundamental
- Price
- HEPS $2.81
- APLT $9.63
- Analyst Decision
- HEPS
- APLT Strong Buy
- Analyst Count
- HEPS 0
- APLT 5
- Target Price
- HEPS N/A
- APLT $12.50
- AVG Volume (30 Days)
- HEPS 1.2M
- APLT 1.8M
- Earning Date
- HEPS 12-10-2024
- APLT 11-07-2024
- Dividend Yield
- HEPS N/A
- APLT N/A
- EPS Growth
- HEPS N/A
- APLT N/A
- EPS
- HEPS N/A
- APLT N/A
- Revenue
- HEPS $1,201,171,147.00
- APLT N/A
- Revenue This Year
- HEPS $42.76
- APLT N/A
- Revenue Next Year
- HEPS $39.63
- APLT $3,169.03
- P/E Ratio
- HEPS N/A
- APLT N/A
- Revenue Growth
- HEPS 0.97
- APLT N/A
- 52 Week Low
- HEPS $1.25
- APLT $1.79
- 52 Week High
- HEPS $4.05
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- HEPS 42.65
- APLT 58.33
- Support Level
- HEPS $2.71
- APLT $8.51
- Resistance Level
- HEPS $2.99
- APLT $9.86
- Average True Range (ATR)
- HEPS 0.13
- APLT 0.62
- MACD
- HEPS -0.06
- APLT -0.06
- Stochastic Oscillator
- HEPS 14.29
- APLT 52.74
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues, and other revenues.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.